Also found in: Medical, Encyclopedia, Wikipedia.


 (kär′dē-ō-jĕn′ĭk, -jē′nĭk)
1. Having origin in the heart.
2. Resulting from a disease or disorder of the heart.
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.


originating in the heart, or resulting from a disorder of the heart
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014


(ˌkɑr di əˈdʒɛn ɪk)

originating in the heart; caused by a disorder of the heart.
Random House Kernerman Webster's College Dictionary, © 2010 K Dictionaries Ltd. Copyright 2005, 1997, 1991 by Random House, Inc. All rights reserved.


adj cardiogénico, cardiógeno
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
Mentioned in ?
References in periodicals archive ?
Aurora, CO, August 28, 2019 --( HCA Healthcare/HealthONE's The Medical Center of Aurora today announced that they have been invited to join the National Cardiogenic Shock Initiative (NCSI).
Apart from providing breathing assistance to patients with obstructive sleep apnea (OSA) or sleep apnea/hypopnea syndrome (SAHS), CPAP interface devices are also used for patients with other diseases, including congestive heart failure, acute asthma, cardiogenic pulmonary edema, chronic lung disease and cystic fibrosis.
FDA approval for Impella 5.0 and Impella LD extended duration of use from 6 days to 14 days for cardiogenic shock derived from acute myocardial infarction (AMI) or cardiomyopathy.
The patients were followed up till discharge and all complications like arrhythmias, cardiac failure, cardiogenic shock and death were noted.
M2 PHARMA-May 20, 2019-FDA Approves Impella 5.0 and Impella LD Extended Duration of Use to 14 Days for Cardiogenic Shock Derived from AMI or Cardiomyopathy
Over recent years, use has been declining, as the efficacy and safety of IABP in patients with acute myocardial infarction (MI), with or without cardiogenic shock, has become more controversial.
A recent analysis of 12,675 STEMI patients in the FITT-STEMI (Feedback Intervention and Treatment Times in ST-Elevation Myocardial Infarction) trial emphasizes the strong impact of time delays on mortality, particularly in STEMI patients with cardiogenic shock or out-of-hospital cardiac arrest.
The complaint noted that the three died of lymphoma, cardiogenic shock (with congenital heart disease as an antecedent cause) and tonsillar herniation with lupus as underlying cause.
This condition is generally known to be relatively benign; however, several cases of serious complications, such as cardiogenic shock or fatal arrhythmia have been reported.
A combination of cardiogenic and non-cardiogenic mechanisms usually contributes to the pathogenesis of PE, including negative pressure PE, anaphylaxis, acute lung injury, fluid maldistribution and neurogenic and cardiogenic PE (1).